Zanos, Panos
Moaddel, Ruin
Morris, Patrick J.
Georgiou, Polymnia
Fischell, Jonathan
Elmer, Greg I.
Alkondon, Manickavasagom
Yuan, Peixiong
Pribut, Heather J.
Singh, Nagendra S.
Dossou, Katina S. S.
Fang, Yuhong
Huang, Xi-Ping
Mayo, Cheryl L.
Wainer, Irving W.
Albuquerque, Edson X.
Thompson, Scott M.
Thomas, Craig J.
Zarate Jr, Carlos A.
Gould, Todd D.
Article History
Received: 15 October 2015
Accepted: 12 April 2016
First Online: 4 May 2016
Change Date: 13 May 2016
Change Type: Correction
Change Details: The competing financial interests statement did not display correctly online when this paper was first published; this has been corrected and the statement is now available.
Competing interests
: The authors declare competing financial interests: I.W.W., R.M., and C.A.Z. are listed as co-inventors on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. They have assigned their rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government. I.W.W., C.A.Z., R.M., T.G., P.Z., C.T., and P.M. are listed as co-inventors on a patent application for the use of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorders. I.W.W., C.A.Z., R.M., C.T., and P.M. have assigned their rights in this patent to the U.S. government but will share a percentage of any royalties that may be received by the government. T.G. and P.Z. have assigned their rights in this patent to the University of Maryland but will share a percentage of any royalties that may be received by the University of Maryland.